Two projects win backing from CFTI

- Last updated on GMT

Related tags: Cystic fibrosis, Immune system, Research, Executive officer

Two projects have been selected for preclinical testing as part of the Cystic Fibrosis (CF)Technology Initiative (CFTI) in Canada.

The CFTI – collaboration between Cystic Fibrosis Canada, the University of British Columbia (UBC), and The Centre for Drug Research and Development (CDRD) – say both projects have passed their rigorous "go or no-go decision making process”.

One project, lead by UBC’s Chris Orvig, features a new formulation of an existing antibiotic, ciprofloxacin, combined with gallium to produce a potent therapeutic against infections.

The team say the compound coordinates the atoms to provide a "one-two punch" ​against bacteria.

The second project focuses on the use of a unique peptide from a family termed defensins, discovered by Robert Hancock, which is applied to the cycle of inflammation and infection that damages the lungs of CF patients.

"By providing our highly-specialized scientific and business expertise as well as our state-of-the-art drug development facilities, we aim to accelerate the development of these research projects into innovative therapies for children and adults with cystic fibrosis,"​ said Natalie Dakers, President and Chief Executive Officer of CDRD.

Related topics: Clinical Development, Preclinical

Related news

Related products

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Related suppliers

Follow us

Products

View more

Webinars